Introduction {#s1}
============

Colorectal cancer (CRC) is one of the common malignancies in industrialized countries. Lynch syndrome, a highly penetrant disorder that confers predisposition to cancer of the colorectum, endometrium and other extra-colonic sites [@pgen.1000092-Kunkel1], is caused by germline mutations in DNA Mismatch Repair genes (MMR). Including sporadic forms, defective MMR underlies ∼12--15% of CRC [@pgen.1000092-Ribic1]. MMR plays critical roles in the maintenance of genomic stability in both prokaryotes and eukaryotes [@pgen.1000092-Kolodner1]. The study of model organisms has yielded great insights into the mechanisms through which MMR prevents cancer [@pgen.1000092-Kunkel1],[@pgen.1000092-Kolodner1],[@pgen.1000092-Edelmann1],[@pgen.1000092-Marcon1],[@pgen.1000092-Neuberger1],[@pgen.1000092-Stojic1],[@pgen.1000092-Muller1]. Briefly, there are nine mammalian MMR genes (*MLH1*, *MLH3*, *PMS1-2*, *MSH2-6*). The mammalian E *coli* MutS homologues (MSH) directly contact DNA, scanning along the genomic DNA for mismatches analogous to a "sliding clamp" until they encounter a base-pair containing a mismatch [@pgen.1000092-Fishel1],[@pgen.1000092-Acharya1]. MSH2-MSH6 primarily recognizes single-base substitutions and 1 base-pair insertion-deletion loop (IDL) mutations, while MSH2-MSH3 recognizes 1--4 base-pair insertion-deletion mutations [@pgen.1000092-Kunkel1],[@pgen.1000092-Kolodner1].The IDL repair deficiency is commonly referred to as Microsatellite Instability (MSI). The MSH proteins interact with multiple proteins including the mammalian E *coli* MutL homologues (MLH) and yeast post-meiotic segregation (PMS) homologue proteins (which have significant amino acid identify and structural similarity to the MLH proteins), as well as *RPA*, *EXO1*, *RFC*, *HMGB1*, *POLDC* and other proteins [@pgen.1000092-Kunkel1],[@pgen.1000092-Muller1],[@pgen.1000092-Constantin1],[@pgen.1000092-Dzantiev1]. MLH1-PMS2 is the primary MutL complex that interacts with both MSH2/6 and MSH3 complexes. MLH1--MLH3 is less well characterized, but is believed to participate in IDL repair [@pgen.1000092-Chen1],[@pgen.1000092-FloresRozas1], DNA damage response [@pgen.1000092-Chen1], and possibly single-base point mutation repair (SBR)[@pgen.1000092-Cannavo1]. MLH1-PMS1 exists in mammalian cells but currently has no clearly defined roles in processes related to cancer prevention [@pgen.1000092-Prolla1],[@pgen.1000092-Raschle1].

To study the precise mechanisms through which MMR suppresses carcinogenesis *in vivo*, we and others [@pgen.1000092-Prolla1],[@pgen.1000092-Lipkin1],[@pgen.1000092-Baker1],[@pgen.1000092-deWind1],[@pgen.1000092-Reitmair1],[@pgen.1000092-Reitmair2],[@pgen.1000092-Edelmann2],[@pgen.1000092-Edelmann3] previously developed several mouse models carrying mutations in different MMR genes. *Mlh1^−/−^* and *Msh2^−/−^* mice develop early onset GI epithelial cancers, lymphomas and other types of cancer. *Pms2^−/−^* mice develop lymphomas, but not GI epithelial cancers. *Mlh3^−/−^* mice develop GI and extra-GI tumors, have decreased survival when compared with *Wt* mice, but with later onset than *Mlh1^−/−^* [@pgen.1000092-Chen1]. *Mlh3^−/−^*;*Pms2^−/−^* mice have increased cancer incidence, resistance to apoptosis and MSI [@pgen.1000092-Chen1]. However, the precise mechanisms in which *Mlh3* and *Pms2* participate to suppress GI epithelial tumorigenesis and progression remain poorly characterized.

Germ-line mutations in tumor suppressor gene *APC* lead to familial adenomatous polyposis (FAP) [@pgen.1000092-Groden1],[@pgen.1000092-Kinzler1]. Mutations in *APC* are found in the majority of sporadic CRC and many Lynch syndrome tumors [@pgen.1000092-Huang1],[@pgen.1000092-Konishi1]. APC complexes with AXIN and CK1/2 and destabilizes β-Catenin by enhancing proteasomal destruction. Mutated *APC* proteins are unable to down-regulate β-Catenin, and the stabilized β-Catenin translocates into the nucleus where it acts as a transcriptional coactivator of the DNA binding protein TCF-4 [@pgen.1000092-Gregorieff1],[@pgen.1000092-Reya1]. More than 95% of *APC* germ-line mutations are truncating or nonsense mutations and most of the pathogenic mutations are located within the first 1500 codons. *Apc* mutations cooperate with MMR deficiency in both tumorigenesis and tumor progression. *Apc^1638N^* mice are a well characterized model that develops GI cancer [@pgen.1000092-Smits1]. *Mlh1^−/−^*;*Apc^1638N^* mice showed significantly increased GI tumor multiplicity and accelerated progression to adenocarcinoma compared to either mutation separately. Analyses of GI tumors from *Mlh1^−/−^*;*Apc^1638N^* and *Msh3^−/−^*;*Msh6^−/−^*;*Apc^1638N^* mice revealed that both single-base substitutions and MSI induced frameshift mutations in repetitive sequences were responsible for most mutations found in the remaining wild-type (Wt) *Apc* allele [@pgen.1000092-Kuraguchi1],[@pgen.1000092-Kuraguchi2]. In contrast, tumor-associated *Apc* mutations found in the Wt *Apc* allele in *Msh6^−/−^*;*Apc^1638N^* tumors were predominantly single-base point mutations.

To understand more precisely the mechanistic roles that *Mlh3* and *Pms2* play in GI tumor suppression, we generated *Mlh3^−/−^*;*Apc^1638N^* (*MA*) and *Mlh3^−/−^*;*Pms2^−/−^*;*Apc^1638N^* (*MPA*) mice. We show that *in vivo Mlh3* mutations significantly increase frameshift mutation rates in *Apc*, and increase GI tumorigenesis. Unlike typical MSI-induced mutations, *Mlh3* deficiency also results in frameshift mutations in non-repetitive sequences, a unique mutational signature among MMR deficient mice found only in *Mlh3* deficient mice. Consistent with the role of *Pms2* in SBR, combined *Mlh3* and *Pms2* mutations proportionally increase point mutations and show a sequence preference for a *CpG* mutation hotspot also previously seen in *Mlh1^−/−^* mice. Because *MPA* mutant mice also have significantly increased rates of GI adenocarcinomas vs. *Apc^1638N^* or *MA* mice, we investigated mechanisms of tumor progression. Using array-CGH, we identified a recurrent 5-Mb amplification on chromosome 12 in GI tumors from *MPA* mice. We defined the amplicon critical interval and demonstrated that it contains a previously uncharacterized member of the *Transducin enhancer of Split* (*TLE*)/*Groucho* family of transcriptional co-regulators, *Tle6-like*, that contributes to tumor progression. *Tle6-like* overexpression in colon cancer cell lines increases cell proliferation, colony-formation ability, cell migration and xenograft tumorigenicity. Human *TLE6D*, an alternatively spliced isoform of *TLE6*, with a domain structure similar to *Tle6-like*, has functional activity similar to *Tle6-like*. Both *Tle6-like* and *TLE6D* interact with GI tumor suppressor, *RUNX3* [@pgen.1000092-Li1], and antagonize *RUNX3* gene target tranactivation. *TLE6D* is overexpressed in multiple human microsatellite stable (MSS) and microsatellite unstable (MSI-H) CRCs, and *TLE6D* expression levels correlate with *RUNX3* expression levels. Collectively, these findings provide important insights into the molecular mechanisms through which MMR-deficiency contributes to GI tumorigenesis and implicate a novel association between *TLE6* isoforms and antagonism of *RUNX* target gene expression in CRC tumor progression.

Results {#s2}
=======

*Mlh3*, *Pms2* and *Apc* Mutations Cooperate to Increase Tumor Incidence, Accelerate Progression and Decrease Overall Survival {#s2a}
------------------------------------------------------------------------------------------------------------------------------

By 9.5 months of age, *MA* mice develop \>50% more tumors than *Apc^1638N^* mice (P\<0.001; Mann-Whitney) ([Figure 1A and C](#pgen-1000092-g001){ref-type="fig"}). However, the relative ratios of GI adenomas to carcinomas in *Apc^1638N^* mice (65% and 35% respectively) were very similar to that seen in *MA* mice (70% and 30% respectively) and overall survival is not significantly affected (9.5 vs. 10.5 months). No significant effect was seen on extra-GI cancer incidence or progression. These data suggest the primary role of *Mlh3* is in suppression of GI tumor initiation and not tumor progression.

![Decreased survival and increased tumor multiplicity and progression in *MPA* mice.\
(A) Kaplan-Meier survival analysis of mice deficient in Apc and DNA Mismatch Repair genes. (B, left) Three small intestinal adenomatous polyps from MPA mouse duodena are seen in cross-section (arrows, left panel). (B, right panel) Example of a jejeunal adenocarcinoma from an MPA mouse, showing atypical glands (arrows) invading deeply into a desmoplastic stroma (asterisks) containing a mixed chronic inflammatory reaction (arrowheads). (C) Tumor incidence and multiplicity. ^a^ Data from Chen et al[@pgen.1000092-Chen1]. ^b^ Data from Edelmann *et al* [@pgen.1000092-Edelmann4], for comparison. NA, data not available.](pgen.1000092.g001){#pgen-1000092-g001}

To study the effects of combined *Mlh3* and *Pms2* mutations *in vivo*, we generated *MPA* mice. *MPA* mice had significantly shorter survival vs. *Apc^1638N^* or *MA* mice (P\<0.01, Mann-Whitney test; [Figure 1A, C](#pgen-1000092-g001){ref-type="fig"}) and developed significantly more adenocarcinomas than *MA* or *Apc^1638N^* mice ([Figure 1B, C](#pgen-1000092-g001){ref-type="fig"}) (P = 0.022 *MPA* vs. *MA* and p = 0.0003 *MPA* vs. *Apc^1638N^*). These are consistent with a role for *Mlh3*;*Pms2* combined loss both to increase GI tumor initiation and accelerates progression. However, mean overall survival of MPA mice is longer than that previously seen in *Mlh1^−/−^*;*Apc^1638N^* mice [@pgen.1000092-Edelmann4].

Spectrum of *Apc* Mutations in *MA* and *MPA* Mice Tumors {#s2b}
---------------------------------------------------------

*In vitro* studies have alternatively suggested that *Mlh3* participates in either IDL repair [@pgen.1000092-Chen1] or SBR [@pgen.1000092-Cannavo1]. To understand the role of *Mlh3* in these processes, we used the wild type *Apc* allele as a tumor-associated *in vivo* reporter gene to analyze the mutation spectrum from *MA* GI tumors. A total of 49 tumors from *MA* mice and 28 tumors from *Apc^1638N^* littermates were analyzed for *Apc* truncation mutations by IVTT analysis. Truncated Apc products were detected in 27 of 49 (55%) *MA* tumors while only 9 of 28 (32%) were found in *Apc^1638N^* tumors. The current observed incidence of *Apc* somatic mutations of *Apc^1638N^* tumors is in agreement with the previous results (7 of 22, 32%) [@pgen.1000092-Wong1], hence for better understanding of mutational differences between the two strains, this and the previous data for *Apc^1638N^* tumors were combined and used for further comparisons. This 23% increase in somatic *Apc* mutations in *MA* mice was significant (P\<0.0048; Fisher exact test) and was attributable to increased small insertion/deletion frameshift mutations (62.5%) vs. *Apc^1638N^* (33.3%) mice (P\<0.001; Fisher exact test; [Figure 2B](#pgen-1000092-g002){ref-type="fig"} and [Tables 1](#pgen-1000092-t001){ref-type="table"} and [2](#pgen-1000092-t002){ref-type="table"}). *MA* mice had one recurrent insertion/deletion mutation "hotspot" also observed in *Mlh1*;*Apc^1638N^* mice (amino acid 1464) ([Figure 2A](#pgen-1000092-g002){ref-type="fig"}). Furthermore, examination of the sequences surrounding each *Apc* mutation site in *MA* tumors showed that, unlike in other mismatch repair deficient tumors such as *Mlh1^−/−^*;*Apc^1638N^* or *Msh6^−/−^*;*Msh3^−/−^*;*Apc^1638N^* [@pgen.1000092-Kuraguchi1],[@pgen.1000092-Kuraguchi2], about 40% of frameshift mutations occurred at non-repetitive sequences within the *Apc* coding region. These data are consistent with a primary *in vivo* role for *Mlh3* in DNA repair of small insertion/deletion mutations in GI epithelial cells.

![Distribution of *Apc* mutations.\
(A) Diagram of *Apc* between codons 677 and 1674 showing positions and characteristics of truncation mutations detected in *MPA (top)*, *MA* (middle) and *Apc^1638N^* (bottom) gastrointestinal tumors. (Open triangle symbol, deletion; solid triangle, insertion; blue bar, substitution). Each symbol represents an independent mutation. Note the common hotspots at position 1464 in both strains. The three 15-aa (A--C), four 20-aa (1--4) β-catenin binding repeats and one SAMP repeat in this segment of Apc are indicated. The two nuclear export signals are at the ends of the third and fourth 20-aa repeats. (B) Spectrum of *Apc* truncation mutations in MMR deficient Apc^1638N^ tumors. ^a^ Combined with previous data from Wong et al, 2002. ^b^ Data from Kuraguchi et al, 2000, for comparison.](pgen.1000092.g002){#pgen-1000092-g002}

10.1371/journal.pgen.1000092.t001

###### *Apc* truncation mutations in intestinal tumors from MutL homolog deficient Apc^1638N^ mice.

![](pgen.1000092.t001){#pgen-1000092-t001-1}

                                                          +/+ Apc^1638N^ [a](#nt101){ref-type="table-fn"}   Mlh3^−/−^ Apc^1638N^   Mlh3^−/−^ Pms2^−/−^ Apc^1638N^   Mlh1^−/−^ Apc^1638N^ [b](#nt102){ref-type="table-fn"}
  ------------------------------------------------------ ------------------------------------------------- ---------------------- -------------------------------- -------------------------------------------------------
  Tumor DNA samples analyzed                                                 50 (100%)                           49 (100%)                   49 (100%)                                    44 (100%)
  Tumors samples with Apc truncations detected by IVTT                       16 (32%)                             27 (55%)                    25 (51%)                                    37 (84%)
  Tumor samples showing \>1 mutant allele                                     2 (4%)                              5 (10%)                     4 (8.1%)                                    29 (66%)
  Total *Apc* mutations characterized by sequencing                          18 (100%)                           32 (100%)                    28 (93%)                                    91 (100%)

Combined with previous data from Wong *et al* 2002 [@pgen.1000092-Wong1].

Data from Kuraguchi *et al* 2000 [@pgen.1000092-Kuraguchi1] for comparison.

10.1371/journal.pgen.1000092.t002

###### Sequences of *Apc* mutations in MutL homolog deficient Apc^1638N^ tumors.

![](pgen.1000092.t002){#pgen-1000092-t002-2}

  Codon    Mutation   Conseq- uence                        Wild-type Sequence ^b^                                   Apc^1638N^               Mlh3^−/−^ Apc^1638N^   Mlh3 Pms2^−/−^ Apc^1638N^
  ------- ---------- --------------- ------------------------------------------------------------------ ----------------------------------- ---------------------- ---------------------------
  769        G→T        Glu→Stop                          TTA TCA **G**AA ACC TTC                                       \-                            1                        \-
  778         ΔT       frameshift                         AAC CTA AG**T** CCC AAG                                       \-                            \-                       \-
  803        C→T        Arg→Stop                          GCC AAT **C**GA CAT GAT                                       \-                            2                        \-
  808         ΔG       frameshift                      GAT AGT A[G**G**]{.ul} TCA GAC                                    1                            \-                       \-
  819        ΔTG       frameshift                         ATG AC**T G**TT CTT TCA                                       \-                            1                        \-
  847        ΔAC       frameshift                         GAG AAA G**AC** AGA AGT                                       \-                            1                        \-
  848        ΔAG       frameshift                         AAA GAC **AG**A AGT TTG                                       \-                            1                        \-
  853        ΔAG       frameshift                      G[AG AGA G**AG**]{.ul} CGA GGT                                   \-                            1                        \-
  854        C→T        Arg→Stop                          GAG AGA GAG **C**GA GGT                                       \-                            1                         4
  866        G→T        Glu→Stop                          ACA ACA **G**AA AAT GCA                                       \-                            \-                        1
  871        ΔTC       frameshift                         GGA ACC **TC**A TCA AAA                                       \-                            1                        \-
  872        C→A        Ser→Stop                          ACC TCA T**C**A AAA CGA                                       \-                            \-                       \-
  874        C→T        Arg→Stop                          TCA AAA **C**GA GGT CTG                        1[a](#nt103){ref-type="table-fn"}            \-                        4
  884        C→T        Gln→Stop                          GCA GCC **C**AG ATA GCC                                       \-                            \-                        1
  902        ΔAG       frameshift                         GAC GAC **AG**A AGT TCT                                       \-                            1                        \-
  909        G→T        Glu→Stop                          ACC ACC **G**AG TTC CAT                                       \-                            1                        \-
  913        ΔTG       frameshift                      CAT [TGT G**TG**]{.ul} GCA GAC                                   \-                            1                        \-
  921        C→T        Arg→Stop                          GCG GCA **C**GA AGA AGC                        3[a](#nt103){ref-type="table-fn"}            2                        \-
  933        C→A        Tyr→Stop                          AAC ACA TA**C** AAC TTC                                        1                            \-                       \-
  934       +TACA      frameshift                         AAC ACA **TAC A**AC TTC                        1[a](#nt103){ref-type="table-fn"}            \-                       \-
  939        G→T        Glu→Stop                          AAG TCG **G**AA AAT TCA                                        2                            \-                        1
  944       Δ38bp      frameshift     TCAAATAGGA**CATGCTCTATGCCTTATGCCAAAGTGGAATATAAACGA** TCT TCA AAT                   1                            \-                       \-
  956        C→T        Arg→Stop                          TAT AAA **C**GA TCT TCA                                        1                            1                         1
  959         ΔA       frameshift                      TCT TC[A A**A**]{.ul}T GAC AGT                                   \-                            \-                        1
  974        ΔAA       frameshift                      GGT [AA**AA**]{.ul}GA GGC CAA                                                                                            1
  974        ΔGA       frameshift                         GGT AAA A**GA** GGC CAA                                                                                               1
  984        T→A        Tyr→Stop                          GAA TCC TA**T** TCT GAA                                       \-                            1                        \-
  992         +T       frameshift                      AAA [TTT **T**]{.ul}GC AGT TAT                                   \-                            2                        \-
  992       Δ8bp+A     frameshift                         AAA TT**T TGC AGT T**AT                        1[a](#nt103){ref-type="table-fn"}            \-                       \-
  1004        ΔC       frameshift                      GAC CTA G[CC **C**]{.ul}AT AAG                                   \-                            1                        \-
  1018       G→T        Glu→Stop                          GAT GGA **G**AA CTG GAT                                        1                            \-                       \-
  1025       C→A        Tyr→Stop                          ATA AAT TA**C** AGT CTT                                       \-                            1                        \-
  1025       ΔAC       frameshift                         ATA AAT T**AC** AGT CTT                                        1                            \-                        2
  1047       G→A        Trp→Stop                          GAA AGG TG**G** GCA AGA                        1[a](#nt103){ref-type="table-fn"}            1                         1
  1127        +T       frameshift                         CAG TCT C**T**G TGT CAG                                        1                            \-                       \-
  1127       ΔCT       frameshift                      CAG T[CT **CT**]{.ul}G TGT CAG                                                                                           1
  1128       ΔGT       frameshift                      TCT CT[G T**GT**]{.ul} CAG GAA                                   \-                            1                        \-
  1141       C→A        Tyr→Stop                          ACC AAC TA**C** AGT GAA                                        1                            \-                       \-
  1143       G→T        Glu→Stop                          TAC AGT **G**AA CGT TAT                                        1                            \-                       \-
  1154       G→T        Glu→Stop                          GAA GAA **G**AA GAA GAG                                                                                               1
  1157       ΔGA       frameshift                      GAA [GAG A**GA**]{.ul} CCG ACA                                                                                           1
  1211       ΔTC       frameshift                      CA[T CTC TC**T C**]{.ul}CA AGC                                   \-                            1                        \-
  1219        ΔG       frameshift                         ACA GCT **G**TA CCT CCA                                       \-                            1                        \-
  1227       C→T        Gln→Stop                          AAA AGG **C**AG AAT CAG                                       \-                            \-                        1
  1272       C→A        Cys→Stop                          TCA AGG TG**C** AGT TCA                                       \-                            \-                        1
  1234       C→A        Ser→Stop                          CCA AGT T**C**A GCA CAA                                       \-                            1                        \-
  1244        ΔG       frameshift                      CAA AAA [G**G**]{.ul}C ACT ACT                                   \-                            1                        \-
  1370        ΔA       frameshift                      ACA CCC [AAA **A**]{.ul}GT CCC                                   \-                            1                         1
  1464       ΔAG       frameshift                      GAG A[AG AGA GAG **AG**]{.ul}T                                   \-                            5                         4
                                                                   Total                                                18                            32                       28

Previous data from Wong et al 2002.

We also studied the tumor-associated *Apc* mutations in GI tumors from *MPA* mice. The overall incidence of *Apc* truncation mutations in *MPA* tumors were similar to that observed in *MA* tumors, yet the nature of mutations characterized was distinct. Compared with *MA* mice (37.5%), combined *Mlh3*;*Pms2* deficiency caused a significant increase in the proportion of single-base point mutations (57.2%, P\<0.01; [Figure 2](#pgen-1000092-g002){ref-type="fig"} and [Table 2](#pgen-1000092-t002){ref-type="table"}). Within the types of single-base point mutations, *MPA* tumors showed higher frequency of C∶G→T∶A transition mutations (12 of 16, 75%) compared to *MA* tumors (7 of 12, 58.3%). However, this high frequency was not as prominent as that of *Mlh1*;*Apc^1638N^* tumors which showed the majority (23 of 25, 92%) of base substitutions to be transition mutations[@pgen.1000092-Kuraguchi1]. The C∶G→T∶A transition mutations found in tumors, irrespective of genotypes, occurred at either *CpG* dinucleotides or CpNpG sites, typical targets for DNA methylation. Among these, *Apc* codon R854 seems to be a preferential target for base substitution mutation, which was not only demonstrated to be a mutational hotspot in *Mlh1*;*Apc^1638N^* mice [@pgen.1000092-Kuraguchi1] but also in *MPA* mice.

Identification of Genomic Copy Amplification in *MPA* Tumors Associated with Tumor Progression {#s2c}
----------------------------------------------------------------------------------------------

*Apc* mutation is thought to be an early event in CRC carcinogenesis. The significantly increased number of adenocarcinomas vs. adenomas seen in *MPA* vs. *MA* or *Apc^1638N^* mice suggested that *MPA* tumors have accelerated tumor progression. While there is extensive evidence that increased mutation rates and decreased apoptosis contribute to MMR defective CRC, it is likely that additional mechanisms participate in tumor progression as well. Because chromosomal and segmental aneuploidy has been described in a subset of MMR deficient adenocarcinomas [@pgen.1000092-Campbell1],[@pgen.1000092-Sinicrope1],[@pgen.1000092-Trautmann1], we performed array comparative genomic hybridization (aCGH) analyses of GI tumor vs. E18.5 C57BL/6 embryonic control DNA from *Apc*, *MA*, and *MPA* mice to identify specific genetic changes that accelerate *MPA* GI tumor progression. Comparison of aCGH profiles revealed a recurrent 5-Mb base pairs amplification on chromosome 12F2 (66.7%∼83.3%; see [Table 3](#pgen-1000092-t003){ref-type="table"} for detail; [Figure 3A and B](#pgen-1000092-g003){ref-type="fig"}) in *MPA* GI tumors not seen in *Apc^1638N^* or *MA* tumors ([Figure S1](#pgen.1000092.s001){ref-type="supplementary-material"}). To define the critical interval for this amplification on chromosome 12F2 we bred a new cohort of *MPA* mice and quantified copy number variation in the tumor using real-time quantitative PCR (qPCR) ([Figure 3C](#pgen-1000092-g003){ref-type="fig"} and [Table 4](#pgen-1000092-t004){ref-type="table"}). Using qPCR with primer sets for the six genes within the amplified region and two flanking genes, we identified one gene that showed recurrent increased level of genomic DNA in tumor tissues ([Figure 3C](#pgen-1000092-g003){ref-type="fig"}), *Transducin-like enhancer protein 6-like*, *(Tle6-like*). *TLE* family members act as transcriptional corepressors [@pgen.1000092-Stifani1],[@pgen.1000092-Jennings1] without any intrinsic DNA-binding activity. They are recruited to specific gene regulatory sequences in a context-dependent manner by forming complexes with different DNA-binding transcription factors. Two evolutionarily conserved domains define the *TLE* gene family: an N-terminal glutamine-rich (Q) domain that mediates *TLE* family member heterodimerization, and a C-terminal domain of WD motif repeats that mediates direct interactions with sequence specific DNA binding transcription factors ([Figure 4](#pgen-1000092-g004){ref-type="fig"})[@pgen.1000092-Stifani1],[@pgen.1000092-Jennings1]. Previously *TLE* family members have been described containing only the Q domain, such as *Grg1-S* [@pgen.1000092-Lepourcelet1], or only the WD repeat motif, such as *Grg6/Tle6* [@pgen.1000092-Marcal1]. *Tle6-like* similarly contains only the C-terminal WD repeat domain and had highest amino acid identity (84.4%) with *TLE6* ([Figure 4A](#pgen-1000092-g004){ref-type="fig"} and [Figure S2](#pgen.1000092.s002){ref-type="supplementary-material"}).

![Array-CGH analysis of *Mlh3*;*Pms2*;*Apc* deficient GI tumors.\
(A) Display of CGH signal from a representative tumor genome wide. Red arrow indicates the gain of signal on chromosome 12. (B) Higher resolution view of mouse chromosome 12 signal. Red dot line indicates the amplification. (C) Quantitative PCR of genomic DNA level from *MPA* tumors. Dotted box indicates the amplified region detected by array-CGH. (D) Quantitative PCR of *Tle6-like* level in cDNA from *MPA* tumors. (E) Immunoblot of Tle6-like in *MPA* tumors. N, normal tissues; T, tumors.](pgen.1000092.g003){#pgen-1000092-g003}

![TLE Family.\
Schematic diagram of TLE protein family members. (A) Numbers indicate amino acids. Q, glutamine rich domain; GP, Glycine/praline rich domain; CcN, domain containing putative phosphorylation sites and putative nuclear localization signal; SP, serine/praline rich domain; WD repeats, domain containing series of tandem repeats of tryptophan and aspartic acid residues. (B) Diagram of *TLE6* RNA and alternative splice form *TLE6D* is indicated. *TLE6A* is the full length mRNA transcript. Orange bars indicate position of primer sets for qPCR. Arrows indicate exon-exon junctions.](pgen.1000092.g004){#pgen-1000092-g004}

10.1371/journal.pgen.1000092.t003

###### Amplifications of Chromosome 12.

![](pgen.1000092.t003){#pgen-1000092-t003-3}

  Chromosome    Change   Start Position   Start Band   End Position   End Band     Frequency
  ------------ -------- ---------------- ------------ -------------- ---------- ---------------
  12             Gain     109,044,957      12 q F1     109,106,314    12 q F1    8 /12 (66.7%)
  12             Gain     109,106,314      12 q F1     109,348,509    12 q F1    10/12 (83.3%)
  12             Gain     109,348,509      12 q F1     109,556,449    12 q F1     9/12 (75%)

10.1371/journal.pgen.1000092.t004

###### Primers Used in Real-Time PCR.

![](pgen.1000092.t004){#pgen-1000092-t004-4}

  Primer                   Sequences
  -------------- -----------------------------
  Crip-F             GGCTGCCACATTGAAAGAAT
  Crip-F             TCAGCTGCAGAAGCACAGAT
  Cdc5L-F          TGGCAATATATGCTGTCTTGTAGG
  Cdc5L-F            TGCCTCTTCCTCAAAGTCCT
  Myef2l-F           CATGGTCAGGCCTATCACAA
  Myef2l-F           GACTTCCCTTGGTCATGGTG
  Tle6_F          ACACTATCTTAGGCCTCAAGTTCTCTC
  Tle6_R           AGTCATGCCATAGCATCTGACAGT
  Adam6-F            CACCTGCATCATGTTCAAAAA
  Adam6-R            GACATGGCATCAGATCAGGA
  Igh-a_F         AGCAGTCTGAGGTCTGAGGACACGGCC
  Igh-a_R2          TGCTCTTCAGGAGGTTTTAGTT
  U110086690_F       ATGGAATGGAGTTGGGTCTTT
  U110086690_R       TTTGTCATCGCAGACCCTGT
  Vipr2_F             GTGAGCAGCATCCATCCAG
  Vipr2_R            CCTCTCTGATTCTCCGTTTGG
  Alkbh-F            GTAATGCCTCCCAGAAGTGC
  Alkbh-R            CTGCTGAGCTGGTGAAATTG

RNA and Protein Expression Levels of *Tle6-like* Are Increased in *MPA* Tumors {#s2d}
------------------------------------------------------------------------------

To understand the impact of gene amplification on *Tle6-like* expression, we isolated total RNA from tumor and normal tissues from *MPA* mice and used qPCR to quantify relative *Tle6-like* mRNA expression. As a result of copy number amplification, *Tle6-like* mRNA levels were significantly increased in tumors compared with adjacent normal GI tissue ([Figure 3D](#pgen-1000092-g003){ref-type="fig"}). To understand whether *Tle6-like* protein levels are subsequently increased, we generated anti-Tle6-like specific antisera. Western blot analysis with this antisera demonstrated that *Tle6-like* protein levels are significantly increased in GI tumors compared to surrounding normal GI epithelial tissue from *MPA* mice ([Figure 3E](#pgen-1000092-g003){ref-type="fig"}). Overall, these data suggest increased genomic DNA copy number of *Tle6-like* causes increased mRNA and protein expression of *Tle6-like* in *MPA* tumors.

Expression Level of *TLE6* Alternative Spliced Isoform D (*TLE6D*) Is Increased in Human Colorectal Tumors {#s2e}
----------------------------------------------------------------------------------------------------------

Gene diversity can be generated by several mechanisms, including gene duplication and paralogue evolutionary divergence, and the generation of alternative mRNA splice isoforms that modify coding sequence. The mouse *Tle6-like*-containing amplicon is syntenic to human chromosome 14q33, but amplification of this chromosomal region is not associated with CRC. Upon further analysis, we discovered that 14q33 contains no human ortholog of mouse *Tle6-like*, or any other *TLE* family member. However, when we analyzed *TLE6* mRNAs bioinformatically, we identified a previously identified alternative spliced isoform of *TLE6 (TLE6D)* (Genbank Accession \#BX375733) that contains only the C-terminal WD repeat domain of *TLE6*, and therefore has the same domain structure as mouse *Tle6-like* ([Figure 4B](#pgen-1000092-g004){ref-type="fig"}) To understand expression of *TLE6A* (full-length isoform) and *TLE6D* in human CRC, we generated three sets of RT-PCR primers: one for the *TLE6D* N-terminus, one crossing the splice junction that is specific for *TLE6D* and one that detects *TLE6A* but not *TLE6D* ([Figure 4B](#pgen-1000092-g004){ref-type="fig"}). We then calculated expression of these transcripts in 40 human CRC samples and normal tissue. Compared to adjacent normal tissue, the *TLE6D*-specific and *TLE6* C-terminus qPCR showed significantly increased expression in a subset of human CRCs ([Figure 5A](#pgen-1000092-g005){ref-type="fig"}), but not for the *TLE6* N-terminal or *TLE6A* qPCR (data not shown). These data suggest that the *TLE6D* isoform specifically is overexpressed in a subset of human CRCs.

![TLE6D and *RUNX3* mRNA expression levels in human colorectal cancers.\
(A,B) Dotplots of *TLE6D* and *RUNX3* expression levels for each of the 40 samples. Expression is shown as fold elevation vs. accompanying normal adjacent mucosa. (C) Superimposed plot of *TLE6D* and *RUNX3* expression levels by sample (Pearson correlation 0.724; Pvalue\<0.001). (D) A scatterplot of log-transformed *RUNX3* by *TLE6D* expression levels along with the least squares estimate of the regression of *RUNX3* on *TLE6D*. Expression levels were log-transformed in the regression analysis due to heavy skewness. Based upon the regression, it was estimated that the geometric mean of *RUNX3* expression increased 0.525 with a 2-fold increase in *TLE6D* expression (95% CI: 0.165, 0.563; p Value\<0.001).](pgen.1000092.g005){#pgen-1000092-g005}

*Tle6-like* and *TLE6D* Enhance Cell Proliferation, Colony Formation, and Cell Migration {#s2f}
----------------------------------------------------------------------------------------

Because GI tumors from *MPA* mice showed increased number of adenocarcinoma than *Apc^1638N^* or *MA* mice, we evaluated whether increased levels of *Tle6-like* can contribute to mechanisms that underlie tumor progression. We generated stable cell 293 cell lines that express *Tle6-like* or *TLE6D*. For both *Tle6-like* and *TLE6D* overexpressing cell lines, cell proliferation rates were significantly increased compared with vector-transfected control cells ([Figure 6A](#pgen-1000092-g006){ref-type="fig"}). Similar results were also seen in HCT116 and 3T3 cells (data not shown). We next tested the effect of *Tle6-like*/*TLE6* expression on the ability to form colonies *in vitro*. Mouse embryonic fibroblasts transfected with *Tle6-like* or *TLE6D* significantly increased colony formation (four-fold and two-fold, respectively) compared with empty vector-transfected control cells ([Figure 6B and C](#pgen-1000092-g006){ref-type="fig"}). We also tested the mobility of the cells transfected with *Tle6-like/TLE6D* by *in vitro* migration assay. Cell lines stably expressing *Tle6-like* or *TLE6D* were able to migrate a significantly longer distance when compared with control cell lines expressing only the vector ([Figure 6D](#pgen-1000092-g006){ref-type="fig"}). In contrast, no effect of *Tle6-like* or *TLE6D* ectopic expression was seen on induction or resistance of apoptosis induced by serum-depletion in culture medium (data not shown). In summary, these results are consistent with a proliferation and migration advantage for tumor cells expressing *Tle6sh* or *TLE6D*.

![Tle6-like and *TLE6D* Enhance Cell Proliferation, Colony Formation, and Cell Migration.\
(A) HCT116 Cell proliferation MTT assay. (B) Representative picture of plates of colony formation assay on MEFs transfected with vector, *TLE6D*, and *Tle6-like*. (C) Plot of number of colonies from colony formation assay. (D) *In Vitro* Cell Mobility Assay. "Wound" was generated by razor blade, clearing the adherent cells on the right side of the slides. Black lines indicate the edge of the "wound". Representative pictures from HCT116 cells transfected with vector, *TLE6D*, and *Tle6-like* are shown.](pgen.1000092.g006){#pgen-1000092-g006}

*Tle6-like* and *TLE6D* Expression Increases Xenograft Tumor Proliferation *in vivo* {#s2g}
------------------------------------------------------------------------------------

Because *Tle6-like* or *TLE6D* ectopic expression increased cell proliferation and migration *in vitro*, we evaluated their impact *in vivo*. We injected HCT116 cells stably expressing *Tle6-like*, *TLE6D* or vector s.c. into nude mice and quantified tumor growth. As expected, HCT116 cells transfected with vector formed xenograft tumors. In parallel, HCT116 cells expressing *Tle6-like* and *TLE6D* formed significantly larger tumors ([Figure 7](#pgen-1000092-g007){ref-type="fig"}). These results suggest that *Tle6-like* and *TLE6D* expression increases CRC cell proliferation and growth, *in vivo*.

![Tle6-like and *TLE6D* Enhance Gastrointestinal Tumor Progression.\
(A) Left panel, Xenograft of HCT116 cell lines expression *Tle6-like* or vector alone. Right Panel, Xenograft of HCT116 cell lines expression *TLE6D* or vector alone. (B) Representative xenograft tumors of HCT116 cells expressing *pCS2+MT* -*Tle6-like*, *pCS2+MT* vector, *pcDNA6/HisA-TLE6D* and empty *pcDNA6/HisA* vector. (C) Tumor weight in HCT116 xenograft tumors expressing *Tle6-like* or empty *pCS2+MT* vector and *TLE6D* and empty *pcDNA6/HisA* vector (Error bars indicate the standard deviation of the mean; p Value\<0.005).](pgen.1000092.g007){#pgen-1000092-g007}

*Tle6-like* and *TLE6D* Interact with the *RUNX3* GI Tumor Suppressor and Antagonize *RUNX3* Mediated Transactivation {#s2h}
---------------------------------------------------------------------------------------------------------------------

*RUNX* genes encode transcription factors that activate or repress transcription of key regulators of growth, survival and differentiation pathways [@pgen.1000092-Blyth1],[@pgen.1000092-Cameron1]. This gene family is defined by the Runt domain, which mediates both protein-DNA and protein-protein interactions with transcriptional co-regulators. *TLE* proteins interact with, and regulate the function of, *RUNX* proteins through direct interactions between the *TLE* WD domain and the Runt domain and the interactions antagonize *RUNX*-mediated transactivation [@pgen.1000092-Blyth1],[@pgen.1000092-Cameron1],[@pgen.1000092-McLarren1],[@pgen.1000092-Javed1],[@pgen.1000092-Yarmus1]. *RUNX3* has been shown to play important roles in GI epithelial cell development and tumorgenesis. Loss of *Runx3* predisposes knockout mice to gastric hyperplasia, indicating a tumor suppressor-like role for this gene [@pgen.1000092-Li1],[@pgen.1000092-Torquati1],[@pgen.1000092-Chi1],[@pgen.1000092-Yano1],[@pgen.1000092-Ito1]. In human gastric cancers, hypermethylation of *RUNX3*, hemizygous deletion and truncating point mutations have been observed [@pgen.1000092-Li1],[@pgen.1000092-Ito1],[@pgen.1000092-Goel1],[@pgen.1000092-Sakakura1],[@pgen.1000092-Nakase1],[@pgen.1000092-Levanon1],[@pgen.1000092-Guo1],[@pgen.1000092-Brenner1]. To test whether Tle6-like/TLE6D interact with RUNX3, we first evaluated sub-cellular localization using immunofluorescence staining in 293 cells co-transfected with *Tle6-like* or *TLE6D* and native *RUNX3* ([Figure S3](#pgen.1000092.s003){ref-type="supplementary-material"}). Using anti-Myc, anti-Xpress and anti-RUNX3 antibodies, we observed that highest levels of Tle6-like and TLE6 and are in the nucleus overlapping with nuclear RUNX3 staining. Furthermore, in 293 cells, transiently transfected with *Tle6-like* or *TLE6D*, endogenous RUNX3 co-immunoprecipitated with anti-Myc or anti-Xpress antibodies ([Figure 8A and B](#pgen-1000092-g008){ref-type="fig"}), suggesting an interaction between Tle6-like/TLE6D and RUNX3. Similar co-localization and co-immunoprecipitation results were seen in HCT116 and 3T3 cells (data not shown). Finally, to evaluate the functional consequences of Tle6-like/TLE6D interaction on RUNX3 transcriptional regulation we used a well characterized *RUNX3* transactivation on promoter target, osteocalcin (OC), fused to a luciferase reporter gene [@pgen.1000092-Javed1]. As expected, transfected *RUNX3* activated luciferase expression in 293, Hela or HCT116 cells ([Figure 8C](#pgen-1000092-g008){ref-type="fig"}, lane 1 and 2). Co-transfection of *Tle6-like* or *TLE6D* decreased *RUNX3* transcriptional reporter activity in a dose-dependent manner ([Figure 8C](#pgen-1000092-g008){ref-type="fig"}), whereas *Tle6-like*/*TLE6D* transfection had no effect on promoters lacking *RUNX3* binding sites, such as the TOPFLASH/FOPFLASH system (data not shown). Taken together, these results are consistent with a model whereby *Tle6-like/TLE6D* expression antagonizes *RUNX3* GI tumor suppressor mediated target gene transactivation through an interaction between the Tle6-like/TLE6D and RUNX3, providing a selective growth advantage for cell proliferation and migration.

![Tle6-like and *TLE6D* Antagonize *RUNX3* Gene Target Transcription.\
(A and B) Tle6-like/TLE6D interacts with endogenous RUNX3 in 293 cells. Left panel represents the immunoblot of protein extracts before immunoprecipitation. Right panel represents the immunoblot after the immunoprecipitation. (C) Luciferase reporter assay. Cells were transient tranfected with indicated plasmids and relative luciferase activities were determined the next day. (Error bars indicate the standard deviation of the mean).](pgen.1000092.g008){#pgen-1000092-g008}

*TLE6D* is Highly Expressed in Human CRCs with High *RUNX3* Expression Levels {#s2i}
-----------------------------------------------------------------------------

In gastric cancer, *RUNX3* activity is most commonly reduced through a mechanism involving *RUNX3* promoter hypermethylation and subsequently decreased mRNA expression. However, its expression levels in CRC have not been well characterized. We therefore used qPCR to evaluate *RUNX3* expression in 40 human CRC and matched normal GI epithelial samples, normalized to *GAPDH* expression. In many CRCs, *RUNX3* expression is low, consistent with a role in GI tumor suppression. However, in a subset of CRCs *RUNX3* expression is paradoxically increased ([Figure 5B](#pgen-1000092-g005){ref-type="fig"}). To test whether elevated *TLE6D* expression is associated with *RUNX3* activation, we used qPCR to analyze *TLE6D* expression levels in the same matched sets of CRCs and normal mucosa. We observed a clear correlation of *RUNX3* and *TLE6D* expression levels (R = 0.723; [Figure 5C](#pgen-1000092-g005){ref-type="fig"}). However, at the same time no clear correlation was seen for *RUNX3* and *TLE6D* expression levels with regard to MSI-H/MSS status or for expression levels of the full length *TLE6* and *RUNX* (data not shown). Overall, in combination with the functional antagonism of *RUNX3* activity by *TLE6D* observed in colon cancer cells, the correlation of *RUNX3* and *TLE6D* expression in human CRCs suggests that *TLE6D* may interact with the *RUNX3* GI epithelial tumor suppressor and inactivate *RUNX3* in a subset of CRCs independent of MSI status. However, further experiments will be required to analyze the association between RUNX3 and TLE6D expression levels and functional interactions in more detail.

Discussion {#s3}
==========

Because *APC* is a common mutation target in MMR-deficient CRC, we created novel mouse models combining different mutations in these genes to analyze their roles in MMR-deficient GI carcinogenesis and progression. The observation that *MA* mice have increased tumor multiplicity but no accelerated tumor progression or decreased survival vs. *Apc^1638N^* mice suggests a primary role for the Mlh1--Mlh3 heterodimer in suppression of GI tumor initiation. While previous *in vitro* studies have alternatively suggested that Mlh1--Mlh3 participates in IDL repair [@pgen.1000092-Chen1] and SBR[@pgen.1000092-Cannavo1],[@pgen.1000092-Harrington1], our study provides the first *in vivo* evidence that *Mlh3* deficiency significantly increases IDL mutation frequency. This type of mutation occurred both at repetitive and non-repetitive *Apc* sequences, implicating its role in repair of both types of IDL ([Figure 2](#pgen-1000092-g002){ref-type="fig"}). Previous studies of *Pms2^−/−^*;*Apc^Min^* mice have shown a primary role for Mlh1-Pms2 in GI tumorgenesis suppression but not tumor progression[@pgen.1000092-Baker2]. We therefore combined these mutations to create *MPA* mice. Like *Mlh1^−/−^*;*Apc^1638N^* mice, *MPA* mice have significantly increased GI tumor multiplicity, accelerated tumor progression and decreased overall survival[@pgen.1000092-Edelmann5] . *MPA* tumors harbor proportionally more C∶G→T∶A (at either CpG or CpNpG sites) transition mutations than *MA* tumors, showing recurrence in certain arginine codons, one of which was at *Apc* codon 854, a SBR hotspot that was also previously seen in *Mlh1^−/−^*;*Apc^1638N^* mice.

In addition to Mlh1-Pms2 and Mlh1--Mlh3, several lines of evidence from our study suggest a potential role for Mlh1-Pms1 in suppression of GI tumorigenesis. First, *MPA* mice have later mean GI tumor onset compared to previous studies of *Mlh1^−/−^*;*Apc^1638N^* mice[@pgen.1000092-Kuraguchi1]. Second, the multiplicity of GI tumors is decreased vs *Mlh1^−/−^*;*Apc^1638N^* mice. Third, two *Apc* insertion/deletion mutation hotspots seen in *Mlh1^−/−^*;*Apc^1638N^* mice have not been detected in *MPA* tumors. These data are consistent with previous studies of yeast *Mlh2p* (orthologue of mammalian *PMS1*) that demonstrate a minor role for this protein in IDL repair [@pgen.1000092-Harfe1].

Because the combination of *Mlh3*, *Pms2* and *Apc* mutations accelerates tumor progression, we searched *MPA* GI tumor specific genetic changes associated with progression using high-resolution aCGH. *MPA* tumors contained a recurrent 5-Mb amplicon with a critical interval containing a novel, poorly characterized member of the *TLE* family of transcriptional co-repressors, *Tle6-like*. Unexpectedly, this *MPA* recurrent amplification hotspot is not detected by aCGH in GI tumors from *Mlh1^−/−^*;*Apc^1638N^* mice (data not shown). The reason for this difference is unclear, but again suggests that Mlh1-Pms1 may play a role in causing chromosomal instability.

*TLE* genes are the mammalian homologues of *Drosophlia groucho* that play critical roles in a wide range of developmental and cellular pathways [@pgen.1000092-Stifani1]. TLE proteins are transcriptional corepressors for specific families of DNA-binding transcription factors, including RUNX proteins[@pgen.1000092-Yarmus1]. In addition, *Tle1/Grg1* has been shown to act as a lung-specific oncogene in a transgenic mouse model [@pgen.1000092-Allen1]. Mouse *Tle6/Grg6* has been shown to synergize with the E2A-HLF oncoprotein in antagonism of *Runx1* transactivation in murine pro-B cells, causing acute leukemogenesis [@pgen.1000092-Dang1]. *Tle6/Grg6* also participates in developmental mechanisms of neurogenesis [@pgen.1000092-Marcal1]. Here, we provide data that a previously uncharacterized TLE family member containing only the WD repeat domain, *Tle6-like*, has amplified gene copy number, mRNA and protein levels in GI epithelial tumors from MMR deficient/*Apc* mutant mice, and is associated with accelerated tumor progression. Consistent with this observation, in functional studies *Tle6-like/TLE6D* enhances cell proliferation, colony-formation, migration and xenograft tumorgenicity. While *TLE* family members have previously been shown to repress *Wnt/*β*-catenin* signaling [@pgen.1000092-Lepourcelet1],[@pgen.1000092-Levanon2],[@pgen.1000092-Brantjes1],[@pgen.1000092-Daniels1], we were unable to demonstrate any *Tle6-like/TLE6D* protein-protein interactions with β*-catenin* or effect of *Tle6-like/TLE6D* overexpression on β*-catenin* reporter gene activity using TOPFlash in transient transfection in colon cancer cell lines (data not shown), suggesting that *Tle6-like/TLE6D* might not be involved in canonical Wnt pathway.

*RUNX* family genes regulate lineage and stage specific gene transcription by direct binding to DNA promoters and enhancer elements [@pgen.1000092-Blyth1],[@pgen.1000092-Cameron1]. Loss of *Runx3* in the mouse results in the development of gastric mucosal hyperplasia, decreased apoptosis and attenuated *TGF-*β anti-proliferative signaling. Consistent with previous observations of interactions between RUNX3 and TLE family members mediated through the Runt and WD repeat domains, respectively [@pgen.1000092-McLarren1],[@pgen.1000092-Yarmus1], we detected an interaction between RUNX3 and Tle6-like/TLE6D by co-immunoprecipitation. Furthermore, we demonstrated that Tle6-like/TLE6D antagonized RUNX3 regulated transcriptional targets. However, while these experiments show an association between RUNX3∶TLE6D interactions and tumor progression, they do not demonstrate mechanistically the functional importance of this interaction in accelerating tumor progression.

Alternative mRNA splicing allows multiple gene products to be produced from a single coding sequence, and through this mechanism a higher diversity of mammalian genes is generated [@pgen.1000092-Brett1]. Several distinct *TLE/Grg* gene alternative splice forms, such as *Grg-1s*, *QD of TLE4*, and *Grg3b* [@pgen.1000092-Lepourcelet1],[@pgen.1000092-Leon1],[@pgen.1000092-Milili1], have been reported. While the human genome does not encode a *TLE6-LIKE* ortholog, a structurally equivalent protein, *TLE6D*, is generated through alternative splicing. The observation that GI adenocarcinomas from both humans and mice use two very distinct mechanisms to amplify *Tle6-like/TLE6D* activity suggests a strong growth advantage and selective pressure for this TLE isoform in tumor progression. Similarly, the correlation between *TLE6D* and *RUNX3* expression in human CRC suggests a model whereby *RUNX3* inactivation by *TLE6D* could be an important factor driving this growth advantage in both MSI-H and MSS CRC. Future studies will be required to understand the mechanistic implications of the interaction between these two proteins in CRC progression in more precise detail.

Materials and Methods {#s4}
=====================

Mouse Lines and Survival Analyses, Tumor Analysis, and *Apc* Mutation Analysis {#s4a}
------------------------------------------------------------------------------

Wild-type (*Wt*), *Pms2^+/−^* and *Mlh3^+/−^* mice were maintained on the 129 Sv/Ev genetic background and intercrossed to generate *Mlh3^+/−^*;*Pms2^+/−^* mice as described before [@pgen.1000092-Chen1]. *Apc^1638N^* mice were backcrossed four times to 129 Sv/Ev and subsequently intercrossed with *Mlh3^+/−^*; *Pms2^+/−^* to generate *Mlh3^−/−^*;*Apc^1638N^* and *Mlh3^−/−^*;*Pms2^−/−^*;*Apc^1638N^* mice. Kaplan-Meier survival curves were generated and statistical significance between genotypes was determined using the Log Rank test as previously performed [@pgen.1000092-Chen1]. All lines of mice were necropsied when they became morbid or moribund. Sacrificed mice were surveyed for tumors and suspicious masses were histology analyzed as previously performed. Statistical analyses of tumor onset and incidence among the different mouse lines were performed using the Mann-Whitney test as previously described [@pgen.1000092-Edelmann2],[@pgen.1000092-Kuraguchi1],[@pgen.1000092-Kuraguchi2],[@pgen.1000092-Edelmann4],[@pgen.1000092-Yang1],[@pgen.1000092-Yang2],[@pgen.1000092-Velcich1],[@pgen.1000092-Kucherlapati1],[@pgen.1000092-Lin1],[@pgen.1000092-Yang3]. Tumors from stomach, small intestine, and colon were cut into two parts. One part of the tumor was processed for histopathological analysis and the other part was used for DNA/RNA extractions. Genomic DNA samples were extracted using Puregene DNA Isolation kit (Gentra Systems, Minneapolis, MN) and subjected to mutational analysis of *Apc* gene between codons 677--1674 as previously described [@pgen.1000092-Kuraguchi2].

Array Comparative Genomic Hybridization Analysis {#s4b}
------------------------------------------------

Genomic DNAs were isolated from tumor tissue and tail tissue from each mouse using PUREGENE DNA Isolation kit (Gentra Systems, Minneapolis, MN). DNAs were digested with *Dpn*II and subsequently purified using the QIAquick PCR Purification kit (Qiagen). The quality of the DNA samples was evaluated using the Agilent 2100 BioAnalyzer. The purified fragmented DNA samples were random-prime labeled with either Cy5 or Cy3 and hybridized as previously described [@pgen.1000092-Wang1]

Briefly, for each labeling reaction, 2 µg of purified digested DNA were used. Each sample was dye-swap labeled for hybridization to mouse 70-mer oligonucleotide microarrays (Agilent Technologies, Palo Alto, CA) containing 20,281 clones. After hybridization, the arrays were scanned using an Agilent Microarray DNA scanner (Agilent Technologies) and the spot intensity was extracted from slide images using Agilent Feature Extraction Software 7.0. The data were further analyzed using the procedures of Automatic Data Analysis Pipeline (ADAP). Only spots with fluorescence intensities statistically different from the surrounding background (*P*\<0.001) were considered reliable, taking up \>85% of total spots on the chip. For further analysis the fluorescence intensity values of reliable spots were transformed to log2. To minimize the effect of the variations, the log2 intensity ratios of remaining spots were subjected to normalization by Lowess fitting. Gene copy number changes for each sample was calculated by taking the median of the normalized log2 intensity ratios of dye-swapped chip experiments for the corresponding sample. The gene copy numbers were ordered along chromosomes by the map positions of corresponding genes. To eliminate systematic noise, gene copy number changes (log2Ratios) along the chromosomes were smoothed by taking a moving median of symmetric 5-nearest neighbors, followed by Lowess fitting (f = 0.2). The mean and standard deviation (SD) of smoothed log2Ratios for all genes in all the samples were calculated. The copy number profiles of at least 5 consecutive genes that deviated significantly above mean+3SD were interpreted as regional gains, below mean-3SD as regional losses. The threshold for whole chromosomal gain/loss was mean±2SD. The ideograms of chromosomal aberrations were drawn using mapping information of cytogenetic bands to the mouse genome (NCBI Mapview Build 32).

cDNA Preparation and Real-Time PCR {#s4c}
----------------------------------

For RNA extractions, Trizol reagent (Invitrogen) was used to isolate total RNA. RNA were further digested with RNAse-free DNAseI (Promega) and cleaned with RNeasy Mini kit (Qiagen). High Capacity cDNA Archive kit from Applied Biosystems was used to make cDNA from the RNA samples. Real-time quantitative PCR was performed with either SYBRGreen PCR master mix or Taqman PCR master mix (Applied Biosystems) following the manufacture\'s protocol on ABI 7900 machine. Primers used for SYBR Green assays are listed in [Table 1](#pgen-1000092-t001){ref-type="table"}. Each gene was normalized to the internal control gene *Gapdh* and then compared to a known single copy gene (*Alkbh*), which is located on non-amplified region on chromosome 12 D3 in the *MPA* tumors.

Generation of Tle6-Like Antibody {#s4d}
--------------------------------

The whole *Tle6-like* gene (encoded 240 amino acids) was cloned in to pET28b vector and Tle-6like protein was induced and purified from *E. coli*. Rabbit anti-serum was raised against Tle6-like protein. The anti-serum was further purified using affinity column, in which Tle6like protein was covalently bound to CNBr-activated Sepharose 4B (Sigma). The purified antibody was used in immunoblotting at 1∶100 dilutions.

Cell Culture {#s4e}
------------

HCT116, 293, Hela or 3T3 cells were maintained in DMEM with 10%FBS and transfected using Lipofectamine 2000 (Invitrogen). The human isoform *TLE6D* cDNA clone was purchased from Invitrogen (Full-length Human Clones CS0DC017YC05; Accession number BX375733). *Tle6-like* was cloned from cDNA samples from *MPA* mice. We subcloned *Tle6-like* and *TLE6D* into either Xpress-epitope-tagged pcDNA6/HisA vector (Invitrogen) or Myc-tagged pCS2+MT vector. Cells were transfected with following plasmids: *pcDNA6/HisA*, *pcDNA6/HisA-Tle6-like*, *pcDNA6/HisA-TLE6D*, *pCS2+MT*, *pCS2+MT-Tle6-like*, *pCS2+MT-TLE6D*. Stable cell lines from each transfectant were generated with the selection medium containing 10 µg/ml blasticidin (Calbiochem) for 10 days. The pooled populations of cells that survived were used in the experiments for MTT assay and cell mobility assay. The transient-transfected cells were used for colony formation assay, immunoprecipitation, and reporter assay.

MTT Cell Proliferation Assay and Colony Formation Assay {#s4f}
-------------------------------------------------------

For the cell proliferation assay, 4000 cells were plated in 96-well plates and MTT assay were used to determine the cell numbers in a time-course experiment. Briefly, cells were washed with PBS and treated with 5 µg/ml MTT (\[3-(4,5-dimethylthiazol-2-yl)- diphenyltetrazolium bromide\]Sigma, St. Louis, MO) for 5 hours. After removal of MTT, DMSO was added to dissolve the dark purple formazam crystals in the viable cells and absorbance of 600 nm were determined by a multiwell scanning spectrophotometer. The cell numbers were calculated with a control standard curve. For colony-formation assay, MEF cells were seeded in 6 well plates and transient-transfected with 1 µg of the respective plasmids in the next day. After 24 h, cells were trypsinzed, transferred to 10-cm plates and allowed to grow with the selection medium containing 10 µg/ml blasticidin for 2 weeks. Survived cells were fixed in 30% ethanol and stained with 0.25% methylene blue. Colonies containing more than 50 cells were counted. Both assays were repeated three times in three independently-derived cell lines.

*In Vitro* Cell Mobility Assay {#s4g}
------------------------------

The monolayer "wounding assay" was used to demonstrate the *in vitro* cell migration. Human colon cancer HCT116 cells stably expressing corresponding plasmids were plated on glass microscopy slides and cultured to confluence. A "wound" was generated by scratching the slide with a razor blade, clearing a portion of adherent cells on the slide. Photo documentation was taken at day 4 and the migration of cells from the cut edge of the monolayer into the clear portion of the slides was assessed. Two independently-derived stable cell lines for each plasmid were used in this assay.

Antibodies, Immunoprecipitation, and Immunoblotting {#s4h}
---------------------------------------------------

Transient-transfected 293 cells in 10-cm plate were lysed with 1 ml of NP-40 lysis buffer and prepared as described before [@pgen.1000092-Chen1]. Five hundred µl of lysates were pre-cleared with 50 µl ProteinA/G agarose beads (Santa Cruz) for 1 h. After spinning down the ProteinA/G beads, the collected supernatants were incubated with 5 µg anti-Xpress or anti-myc monoclonal antibody (Invitrogen) and 50 µl ProteinA/G beads overnight at 4°C. The next day, the beads were washed with NP-40 buffer 5 times and incubate with 4× protein loading dye (Invitrogen) 10 min at 95°C to elute the binding proteins. These samples were resolved by SDS-PAGE and the immunoblotting was used as previously described to detect the corresponding proteins. The antibodies used in immunoblotting are: mouse monoclonal anti-Xpress and anti-myc (1∶2000, Invitrogen), rabbit anti-RUNX3 (1∶1000, Abcam) and goat anti-β-actin (1∶1000, Santa Cruz Biotechnologe).

Luciferase Reporter Assay {#s4i}
-------------------------

293, Hela or 3T3 cells were transient-transfected accordingly with the *Flag-RUNX3* (a kind gift from Dr. Yoshiaki Ito) and rat Osteocalcin promoter fused to luciferase reporter construct (OC-Luci, a kind gift from Dr. Gary Stein), and plasmids as described above. Luciferase activities were determined using Dual-Luciferase reporter assay systems kit (Promega) on the luminemeter.

Tumor Growth in Nude Mice {#s4j}
-------------------------

Female 6-week-old nude mice (Charles River Laboratories, Wilmington, MA) were divided into four experimental groups, five for each. One million HCT116 cells stably transfected with vectors (*pCS2+MT* or *pCDNA6/HisA*), *pCS2+MT-Tle6sh*, or *pCDNA6/HisA-TLE6D* were injected subcutaneously in the flanks of each mice. Mice were monitored daily for palpable tumors. Because of rapid growth, tumors were dissected out 3 weeks after injection and were analyzed.
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(0.07 MB PPT)

###### 

Click here for additional data file.

###### 

Protein sequences of TLE family.

(1.95 MB PNG)

###### 

Click here for additional data file.

###### 

Cellular localization of endogenous *RUNX3* and transfected Myc-epitope tagged *Tle6-like* in 293cells. Mouse monoclonal anti-myc and rabbit anti-RUNX3 were used. Secondary FITC-conjugated anti-mouse and Cy5-conjuaged anti-rabbit antibodies were used respectively. DAPI (4′,6-diamidino-2-phenylindole) staining indicates the nuclear location.
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